comprehensive -WSS

comprehensive

author：comprehensive 2025-09-30 20:35:46 - browse：44876

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Quicker fix for pulse oximeters urged during FDA public meeting

Wikipedia

WSS

Congressmen charge Covid hearing ‘could have been an email’

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

HCA says smaller share of spending going to labor

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Vertex non

Medicare drug price negotiation’s day in court

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Walensky prepares to leave CDC — and Congress — behind

Doctors increasingly discourage vaping amid mounting health concerns

Malaria cases in Florida and Texas: Here’s what you need to know

Philippine ferry was overloaded when it flipped over, leaving 27 dead, official says

Hepatitis C has a cure — but many Americans still lack access to it

Europe is fastest

Sports medicine is finally prioritizing gender equality

Medicare drug price negotiation’s day in court

Hollywood unions extend contract negotiations for actors

Vertex non

leisure time

ARCH Venture Partners is raising $3 billion for a life sciences fund

Adidas to release second batch of Yeezy sneakers after breakup with Ye

Poland's lawmakers approve a divisive law on Russian influence

Trump PAC spent more than $40M on legal bills this year as his charges mount: Sources

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

focus

Wikipedia

leisure time

focus